Comparación de la eficacia terapéutica entre Adalimumab y Etanercept, en el tratamiento de psoriasis grave, en los pacientes que acuden a consulta del Hospital Manuel Ygnacio Monteros Valdivieso del IESS de Loja, desde el 25 de septiembre del 2012 al 25 de junio del 2013
Psoriasis is a skin disease characterized by a chronic evolution that evolves outbreaks and has clinical variables. The cutaneous manifestations of this disease are so characteristic so that is easy to diagnose. Nowadays, the specialists contemplate the psoriasis as an immunological underlying disea...
সংরক্ষণ করুন:
প্রধান লেখক: | |
---|---|
বিন্যাস: | bachelorThesis |
ভাষা: | spa |
প্রকাশিত: |
2014
|
বিষয়গুলি: | |
অনলাইন ব্যবহার করুন: | http://dspace.unl.edu.ec/jspui/handle/123456789/12436 |
ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
সংক্ষিপ্ত: | Psoriasis is a skin disease characterized by a chronic evolution that evolves outbreaks and has clinical variables. The cutaneous manifestations of this disease are so characteristic so that is easy to diagnose. Nowadays, the specialists contemplate the psoriasis as an immunological underlying disease measured by T lymphocytes, which associates dermal inflammation and secondarily epidermal hyperplasia. It’s probably the dermatological disease immunologically mediated more prevalent. With this research I’m seeking to analyze the therapeutic efficacy between Adalimumab and Etanercept in the treatment of severe psoriasis in patients who attended to dermatology service in Manuel Ygnacio Monteros Hospital, Loja IESS. Using the Scientific Method and by collecting data through a personal file for each patient the same that includes: PASI score to see the severity of the same ones and the poll based on some data as well as (two controls, the first at 6 weeks and the second at 12 weeks after applying the medication). With this research concludes that the Adalimumab is more effective than Etanercept for achieving remission in 73.33% versus 60.1% respectively, phenotype 2 is the most affected with 56.68%, the male is affected by 63.33 %, the diseases that are associated with Psoriasis Diabetes Mellitus type 2 (23.34%), arterial hypertension (10.10%) acute renal failure (3.33%) and Congestive Heart Failure (3.33%) and occurrence of adverse effects were observed as the carcinoma neuroendocrine in (6.66%) with the administration of Adalimumab Keywords: Psoriasis, Score Pasi, Adalimumab and Etanercept, Treatment. |
---|